Media Room
Year-End Late-Stage Pipeline Review
Sanofi is pleased to invite investors and analysts to participate in a year-end late-stage pipeline review by R&D management on Tuesday, December 16, 2025.
Press releases
November 25, 2025
Press Release: Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria
November 14, 2025
Press Release: Sanofi’s Teizeild recommended for EU approval by the CHMP for patients with stage 2 type 1 diabetes
Contact Our Media Team
You are a journalist and have a question about Sanofi, please contact the Global Media relations team. Please note the contact details are only for journalists.
Publications
Half year 2025 financial report XBRL package
Half Year 2025 Financial Report
Sustainability Statement 2024 (ESG Report)
Registration Document 2024 (in French)